Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 6, Pages 2959-2966
Publisher
American Society for Microbiology
Online
2012-02-28
DOI
10.1128/aac.05424-11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers
- (2011) Lingzhi Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-Term Safety from the Raltegravir Clinical Development Program
- (2011) Hedy Teppler et al. CURRENT HIV RESEARCH
- Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
- (2011) J. Ashby et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration
- (2011) A. Fayet Mello et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects
- (2011) D. Cattaneo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
- (2011) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration
- (2010) Silvia Baroncelli et al. ANNALS OF PHARMACOTHERAPY
- Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers
- (2010) M. Neely et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients
- (2010) José Moltó et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
- (2010) Li Zhu et al. ANTIVIRAL THERAPY
- Raltegravir
- (2010) Jamie D. Croxtall et al. DRUGS
- Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies
- (2010) David M Burger Expert Opinion on Drug Metabolism & Toxicology
- Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures
- (2010) Alexandra U Scherrer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
- (2010) D. da Silva et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Integrase inhibitors in the treatment of HIV-1 infection
- (2010) W. G. Powderly JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics
- (2010) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients
- (2010) Dario Cattaneo et al. THERAPEUTIC DRUG MONITORING
- Effects of Omeprazole on Plasma Levels of Raltegravir
- (2009) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
- Sex Differences in Pharmacokinetics and Pharmacodynamics
- (2009) Offie P. Soldin et al. CLINICAL PHARMACOKINETICS
- Drug Interactions with New and Investigational Antiretrovirals
- (2009) Kevin C. Brown et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
- (2009) LA Wenning et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Identification and Profiling of Circulating Metabolites of Atazanavir, a HIV Protease Inhibitor
- (2009) R. t. Heine et al. DRUG METABOLISM AND DISPOSITION
- Gender and interindividual variability in pharmacokinetics
- (2009) Jean-Marie Nicolas et al. DRUG METABOLISM REVIEWS
- Analysis of inherited genetic variations at theUGT1locus in the French-Canadian population
- (2009) Vincent Ménard et al. HUMAN MUTATION
- A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
- (2009) A. Fayet et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
- (2008) M. S. Anderson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
- (2008) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
- (2008) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects
- (2008) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started